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Abstract
Background: Obesity increases risk of hypertension and diabetes, the leading causes of end-stage renal disease.
The effect of obesity on kidney function decline in stable post-myocardial infarction patients is poorly documented.
This relation was investigated in a large cohort of older post-myocardial infarction patients.
Design: Data were analysed from 2410 post-myocardial infarction patients in the Alpha Omega Trial, aged 60–80 years
receiving optimal pharmacotherapy treatment (79% men, 18% diabetes).
Methods: Cystatin C based estimated glomerular filtration rate (eGFRcysC) was calculated at baseline and after 41
months, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Obesity was defined as
body mass index 30 kg/m2 and high waist circumference as 102 and 88 cm for men and women. The relation
between body mass index, waist circumference and annual eGFRcysC decline was evaluated by linear regression.
Results: At baseline, mean (standard deviation) eGFRcysC was 81.5 (19.6) ml/min/1.73 m
2, 23% of all patients were
obese. After multivariable adjustment, the annual mean (95% confidence interval) eGFRcysC decline in men and women
was –1.45 (–1.59 to –1.31) and –0.92 (–1.20 to –0.63) ml/min/1.73 m2, respectively (p¼ 0.001). Obese versus non-obese
patients and patients with high versus normal waist circumference experienced greater annual eGFRcysC decline. Men and
women showed an additional annual eGFRcysC decline of –0.35 (–0.56 to –0.14) and –0.21 (–0.55 to 0.14) ml/min/1.73 m
2
per 5 kg/m2 body mass index increment (p for interaction 0.3).
Conclusions: High compared to normal body mass index or waist circumference were associated with more rapid
kidney function decline in older stable post-myocardial infarction patients receiving optimal drug therapy.
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Introduction
The prevalence of obesity has increased to epidemic
proportions and is ranked globally in the top five risk
factors for death.1 Obesity, defined as a body mass
index (BMI) of 30 kg/m2, is associated with
an increased risk of cardiovascular morbidity and
mortality, as well as accelerated kidney function
decline.1–3 Impaired kidney function itself is a robust
and independent risk factor for cardiovascular morbid-
ity and mortality.4 The annual rate of kidney function
decline in post-myocardial infarction (post-MI)
patients is more than double that of the general
population.5,6
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Obesity may promote kidney damage through both
haemodynamic and hormonal effects. The deleterious
effects of obesity on the kidney are, in part, mediated by
cardiovascular risk factors such as diabetes mellitus,
hypertension and dyslipidaemia.1 Additionally, accu-
mulation of visceral fat can increase production of
inflammatory mediators by adipocytes, contributing
to glomerular and interstitial fibrosis.7 Furthermore,
obesity is associated with an increase in the single-
nephron glomerular filtration rate, which may lead to
glomerulosclerosis and subsequent progressive loss of
kidney function.8
Several studies have suggested a paradoxical effect of
obesity in individuals with pre-existing chronic illness,
such as chronic kidney disease, showing that obesity is
associated with improved survival or kidney func-
tion.9,10 This ‘obesity paradox’ challenges current
guidelines, which advise weight reduction towards an
ideal BMI of 20–25 kg/m2.11
The aim of this study was to assess the association
between obesity and the rate of kidney function decline
in older post-MI patients receiving state-of-the-art drug
treatment, separately for men and women, who differ in
body composition. These results might inform care
guidelines for post-MI patients.
Methods
Study design
This is a secondary analysis of the prospective Alpha
Omega Cohort Study (ClinicalTrials.gov no.
NCT03192410). The cohort consists of patients included
in the Alpha Omega Trial, a randomised controlled trial
of omega-3 (n-3) fatty acid supplementation undertaken
in 4837 patients aged 60–80 years with a verified history
of MI. Patients received state-of-the-art antihyperten-
sive, antithrombotic and lipid-modifying drug treat-
ment, as described in detail elsewhere.12 The trial
started in 2002 and ended in 2009. For this study,
patients were selected from whom non-fasting blood
was drawn at baseline and after 41 months. Owing to
financial constraints, two blood samples were obtained
in only 2426 patients (50% of the cohort), i.e. those
randomised before August 2005. Of all patients rando-
mised prior to August 2005 (n¼ 2918), 233 patients died
during follow-up, 259 patients had missing blood
samples or declined to participate, and 16 patients had
missing data on BMI and/or waist circumference (WC),
yielding an evaluable cohort of 2410 patients
(Supplementary Material, Figure S1). The study was
conducted in accordance with the Helsinki Declaration
and was approved by a central and local medical ethics
committee in the Netherlands. Written informed
consent was obtained from all patients.
Body mass index and waist circumference
Body weight and height were measured with the subject
wearing light indoor clothing without shoes. BMI was
calculated as weight in kilograms divided by the square
of height in meters. Following World Health
Organization (WHO) guidelines, normal weight was
defined as a BMI of 18.5–24.9 kg/m2, overweight as a
BMI of 25.0–29.9 kg/m2 and obesity as a BMI of
30.0 kg/m2 or greater.1 WC, measured at the midpoint
between the bottom rib and the top of the hipbone, was
used as a proxy of visceral fat. Men with a
WC 102 cm and women with a WC 88 cm were
considered to have a high risk of metabolic complica-
tions, hereafter referred to as high, as opposed to
normal, WC.1
Kidney function assessment
At baseline and after 41 months follow-up we measured
from stored blood serum cystatin C (cysC) using a par-
ticle-enhanced immunonephelometric assay and serum
creatinine (cr) by the modified kinetic Jaffé method, as
previously described in detail.4 We estimated glomeru-
lar filtration rate (eGFR) with cysC alone and
the combined cr-cysC Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equations
from 2012, taking into account age, sex and race.13
In the main analyses, results are shown for eGFRcysC,
as it is recommended for confirmatory testing in the
current Kidney Disease - Improving Global Outcomes
(KDIGO) guidelines.11 In the Supplementary Material
the results are presented for eGFRcr-cysC. The change
(or slope) of the eGFRcysC and eGFRcr-cysC from base-
line to 41 months was calculated for each patient by
subtracting the eGFR at baseline from the eGFR after
41 months. Assuming a linear kidney function decline
during follow-up, we then calculated an annual decline
rate. Rapid kidney function decline was defined as an
annual eGFRcysC decline of 3ml/min/1.73 m
2.14
Data collection
Patients were interviewed and physically examined by
trained research nurses at home or in the hospital at
baseline and after 41 months. Lipid, glucose and
high-sensitivity C-reactive protein (hsCRP) levels were
determined as described elsewhere.15 Information on
demographic variables, lifestyle habits, current health
status, and medical history were collected by self-admi-
nistered questionnaires, as previously described.12
Questionnaires were checked by research nurses.
Diabetes mellitus was considered present in the case
of a self-reported physician diagnosis, use of glucose-
lowering drugs, and/or elevated blood glucose. We used
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the average of two blood pressure measurements after a
10-minute seated rest. Medication was coded according
to the Anatomical Therapeutic Chemical (ATC)
Classification System.
Data analysis
Baseline characteristics are presented as mean (stand-
ard deviation (SD)), median (interquartile range), or
number (percentage) as appropriate. Missing data on
level of education (n¼ 14) were imputed by the sex-
specific mode. The relation between BMI or WC and
kidney function decline met the linear regression
assumptions.
Analysis of covariance (ANCOVA) was used to
calculate mean annual eGFR decline rates per WHO
category of BMI and for high and normal WC. Normal
BMI or normal WC was applied as the reference
category. In these analyses, two patients with a
BMI< 18.5 kg/m2 were excluded. Linear regression
was used to study the association between BMI or
WC as continuous variables and kidney function
decline. Regression coefficients were calculated per
5 kg/m2 increment of BMI (approximately one SD),
corresponding to the width of each WHO category;
and per 10 cm increment of WC, which approximately
corresponds to a 5 kg/m2 increment of BMI.16
The continuous relation between each indicator of
body fat (BMI and WC) and kidney function decline
was further analysed in a flexible manner using four-
knot restricted cubic splines with 95% confidence inter-
vals (CIs). As per general guidelines, the knots were
chosen at the 5th, 35th, 65th and 95th percentile of
the BMI and WC distribution for men and women
separately.17
All analyses were adjusted for the n-3 fatty acid
treatment groups of the Alpha Omega Trial (three
dummy variables). In addition to the treatment
group, we adjusted for age at baseline and sex (model
1). According to the WHO, smoking of cigarettes, alco-
hol consumption and socio-economic status may con-
found the association of obesity with outcome.
Therefore, in model 2 (full model), an additional adjust-
ment was made for these baseline factors: current cig-
arette smoking (yes, no), alcohol use (yes, no), and level
of education (elementary education, low, intermediate
and high education) as a proxy for socio-economic
status. Analyses were not adjusted for baseline eGFR,
since baseline-adjustment in models with change-scores
as outcome variable results in biased estimates.18 In the
main analyses we did not control for variables con-
sidered likely causal intermediates in the relation
between obesity and kidney function decline, such as
blood pressure, diabetes, and low-density lipoprotein
(LDL)-cholesterol.
Several sensitivity analyses were performed. First,
we included factors in the causal pathway, diabetes,
systolic blood pressure and LDL-cholesterol, to esti-
mate the presence of mediation. In a separate analysis
we controlled for use of renin-angiotensin system
(RAS) blocking drugs and physical activity. We
explored the presence of effect measure modification
between treatment group and BMI or WC with
regard to kidney function decline. Finally, we investi-
gated the potential relation between change in BMI or
WC from baseline to 41 months follow-up and annual
eGFR decline. The main analyses were repeated using
eGFRcr-cysC decline as outcome. All results are pre-
sented for men and women separately, given previously
reported differences in kidney function decline between
men and women.
Two-sided p-values< 0.05 were considered statistic-
ally significant. All analyses were performed using SPSS
23.0 (SPSS, Inc., Chicago, Illinois, USA) and STATA




Of all patients, the mean age was 69 years, 79% were
men, and 99% were white, median time since MI was
4.0 years. Baseline characteristics according to BMI
categories (normal weight, overweight and obesity)
are presented in Table 1. Patients with overweight or
obesity compared to normal weight had diabetes more
often, used blood-pressure-lowering drugs more often,
had higher serum cholesterol levels, higher hsCRP
levels and lower baseline eGFRcysC. A similar trend
was observed when comparing low and high WC cate-
gories (Supplementary Material, Table S1). Mean (SD)
baseline BMI was 27.5 (3.3) kg/m2 for men and 28.4
(4.6) kg/m2 for women. Mean (SD) WC at baseline was
102 (9) cm for men and 97 (12) cm for women.
Compared to men, women had diabetes more often,
used blood-pressure-lowering drugs more often
(Supplementary Material, Table S2). BMI and WC
were strongly correlated (Pearson correlation coeffi-
cient 0.8). Each 1 kg/m2 increment of BMI was asso-
ciated with an additional 2.2 (95% CI: 2.1 to 2.3) cm
increment of WC.
Baseline kidney function
At baseline, mean (SD) eGFRcysC was 83.3 (19.3) ml/
min/1.73 m2 for men and 74.3 (18.8) ml/min/1.73 m2 for
women. In obese, compared to normal weight, men and
women the mean eGFRcysC was 81.1 versus 84.5ml/
min/1.73 m2 (p¼ 0.006), and 69.1 versus 78.1ml/min/
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Table 1. Baseline characteristics of 2408 post-myocardial infarction patients, stratified by three categories of weight







Age, years 69.3 5.4 69.0 5.4 68.0 5.5
Men, no (%) 419 (79.5) 1116 (84.0) 379 (68.5)
Ethnicity, white, no. (%) 522 (99.1) 1310 (98.6) 548 (99.1)
Higher education,a n (%) 77 (14.6) 171 (12.9) 49 (8.9)
Current smoking, no. (%) 106 (20.1) 188 (14.2) 89 (16.1)
Alcohol use,b n (%) 388 (73.6) 1004 (75.6) 352 (63.7)
Height, cm 172.5 7.9 173.1 7.8 170.0 8.8
Weight, kg 69.6 7.8 82.0 8.3 94.7 11.7
Body mass index, kg/m2 23.3 1.4 27.3 1.4 32.7 2.7
Waist circumference, cm 91.6 7.3 100.9 6.7 111.3 9.2
Physically active,c n (%) 119 (22.6) 319 (24.0) 92 (16.6)
Time since myocardial infarction, years 3.6 (1.6–6.1) 4.0 (2.0–6.3) 4.5 (2.4–6.9)
Diabetes,d n (%) 65 (12.3) 217 (16.3) 162 (29.3)
Systolic blood pressure, mm Hg 141.3 21.8 144.3 21.4 142.8 20.7
Diastolic blood pressure, mm Hg 79.4 10.6 82.0 10.7 82.0 10.5
Antihypertensive drugs,e n (%) 449 (85.2) 1141 (85.9) 505 (91.3)
ACE inhibitors/ATII blockers 265 (50.3) 704 (53.0) 330 (59.7)
Beta blockers 324 (61.5) 863 (65.0) 386 (69.8)
Calcium channel blockers 97 (18.4) 248 (18.7) 117 (21.2)
Diuretics 78 (14.8) 242 (18.2) 177 (32.0)
Glucose-lowering drugs,f n (%) 48 (9.1) 159 (12.0) 108 (19.5)
Insulin analogues 11 (2.1) 42 (3.2) 51 (9.2)
Oral glucose-lowering drugs 39 (7.4) 131 (9.9) 81 (14.6)
Lipid-modifying drugs,g n (%) 454 (86.1) 1140 (85.8) 480 (86.8)
Statins 452 (85.8) 1129 (85.0) 477 (86.3)
Antithrombotic agents,h n (%) 516 (97.9) 1294 (97.4) 541 (97.8)
Total cholesterol,i mmol/l 4.78 0.92 4.81 0.94 4.95 0.91
HDL,i mmol/l 1.35 0.36 1.25 0.31 1.19 0.31
LDL,i mmol/l 2.72 0.79 2.74 0.80 2.77 0.80
Triglycerides,j mmol/l 1.41 (1.04–1.91) 1.62 (1.21–2.24) 1.96 (1.51–2.73)
Plasma glucose,k mmol/l 5.6 1.7 5.9 1.8 6.6 2.4
High-sensitivity CRP, mg/l 1.24 (0.62–2.73) 1.58 (0.81–3.37) 2.60 (1.11–4.81)
Serum cystatin C, mg/l 0.96 0.23 0.96 0.24 1.00 0.26
Serum creatinine,l mmol/l 88.4 26.5 90.2 30.1 91.1 30.9
eGFRcysC,
m ml/min/1.73 m2 82.2 19.3 82.3 19.0 78.8 20.9
eGFRcr-cysC,
m ml/min/1.73 m2 79.4 18.4 79.2 18.1 76.0 20.0
ACE: angiotensin-converting enzyme; ATII: angiotensin II; ATC: Anatomical Therapeutic Chemical; CKD-EPI: Chronic Kidney Disease
Epidemiology Collaboration; cr: creatinine; CRP: C-reactive protein; cysC: cystatin C; eGFR: estimated glomerular filtration rate; HDL:
high-density lipoprotein; LDL: low-density lipoprotein; MET: metabolic equivalent task; SD: standard deviation.
Data are reported as number of patients (%), mean SD or median (interquartile range).
Two patients with BMI< 18.5 kg/m2 were not reported in this table.
aDefined as higher vocational education or university.
bDefined as 1 glass per week.
cDefined as three or more metabolic equivalent tasks (METs) during 5 days/week.
dSelf-reported diagnosis by a physician, use of glucose-lowering drugs, or in case of elevated plasma glucose level (126 mmol/l in the
case of patients who had fasted for four hours or 200 mmol/l in the case of non-fasting patients).
eBlood-pressure-lowering drugs: ATC Classification System codes C02, C03, C07, C08, and C09.
fGlucose-lowering drugs: ATC code A10, A10A, A10B, A10X.
gLipid-modifying drugs: ATC code C10, C10AA.
hAntithrombotic agents: ATC code B01.
iTo convert the values for cholesterol to mg/dl, divide by 0.02586.
jTo convert the values for triglycerides to mg/dl, divide by 0.01129.
kTo convert the values for glucose to mg/dl, divide by 0.05551.
lTo convert the values for creatinine to mg/dl, divide by 88.40.
meGFRcysC and eGFRcr-cysC based on the CKD-EPI equations from 2012.
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1.73 m2 (p< 0.001), respectively. Men with a high WC
(102 cm) had a mean eGFRcysC of 81.8ml/min/1.73
m2 compared to 84.9ml/min/1.73 m2 in those with
normal WC (<102 cm) (p< 0.001). Women with high
WC (88 cm) and normal WC (<88 cm) had mean
eGFRcysC values of 73.6 and 76.8ml/min/1.73 m
2
(p¼ 0.08).
Body mass index and kidney function decline
After 41 months of follow-up, mean (95% CI) decline
in eGFRcysC was –4.61 (–5.06 to –4.17) ml/min/1.73 m
2.
Assuming a linear decline in kidney function, this cor-
responds to an annual decline of –1.34ml/min/1.73 m2.
Men and women had an annual eGFRcysC decline of
1.45 and –0.92ml/min/1.73 m2, respectively (mean
difference 0.53, 95% CI: 0.22 to 0.85). Annual rates
of kidney function decline for normal weight, over-
weight and obese patients were –1.25, –1.30 and –
1.59ml/min/1.73 m2, respectively (Table 2). Rapid
annual kidney function decline was observed in 25%
of obese patients and 23% of normal weight patients
(p¼ 0.23). Obese versus normal weight men had an
additional annual eGFRcysC decline of 0.42 (0.85
to 0.02), corresponding to an additional 30% decline
in kidney function. Obese versus normal weight women
had an additional annual eGFRcysC decline –0.35
(1.22 to 0.53) ml/min/1.73 m2, corresponding to an
additional 45% decline in kidney function. Each 5 kg/
m2 increment of BMI was associated with an additional
annual eGFRcysC decline of –0.35ml/min/1.73 m
2 in
men and –0.21ml/min/1.73 m2 in women, correspond-
ing to 25% and 28% of the sex-specific mean annual
kidney function decline in normal weight patients
Table 2. Mean (95% confidence interval (CI)) annual cystatin C based kidney function decline (ml/min/1.73 m2) in 2408 post-
myocardial infarction patients according to body mass index (BMI) and waist circumference (WC) category, overall and for men and
women separately.
All patients Normal weighta (ref) Overweight Obesity Normal WCb (ref) High WC



































































































Normal weight BMI 18.5–24.9, overweight BMI 25.0–29.9, obesity BMI 30.0 kg/m2. Normal and high WC< 88 and 88 cm for women and <102 and
102 cm for men. Kidney function based on the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation from 2012.13 Adjusted variables were fixed at the mean value of the reference group, hence the results of the reference category
are equal across models. Two patients with BMI< 18.5 kg/m2 were not reported in this table.
aReference: annual kidney function decline in normal weight patients.
bReference: annual kidney function decline in normal WC patients.
Model 1: adjusted for treatment group, age and sex (if not stratified for).
Model 2: model 1 plus additional adjustment for current smoking, alcohol use, level of education.
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(Table 3). Supplementary Material, Table S3 shows the
adjusted analysis in more detail. Figure 1(a) depicts the
continuous relation between BMI and annual kidney
function decline for men and women. There was no
effect measure modification between BMI and sex
with regard to kidney function decline.
Waist circumference and kidney function decline
Men and women with high versus normal WC had a
faster annual decline in kidney function (Table 2). In
men, the additional decline in eGFR (95% CI) was
0.39 (0.66 to 0.13) ml/min/1.73m2; for women it
was 0.40 (1.17 to 0.36) ml/min/1.73m2. Among
patients with high and normal WC, 26% and 21%
showed rapid kidney function decline, respectively
(p¼ 0.003). In regression analysis, a squared WC term
was significant in men (p¼ 0.03) but not in women
(p¼ 0.2). For each 10 cm increment of WC there was
an additional annual kidney function decline of
0.21ml/min/1.73m2 in men and –0.22ml/min/1.73m2
in women (Table 3 and Supplementary Material, Table
S3). Figure 1(b) depicts the continuous relation between
WC and annual kidney function decline for men and
women.
Sensitivity analyses
In addition to model 2, further adjustment for diabetes
attenuated the association of BMI (and WC) with
kidney function decline. The regression coefficient
per 5 kg/m2 BMI changed from –0.28 to –0.20
(Supplementary Material, Table S4). Additional adjust-
ment for systolic blood pressure or LDL-cholesterol did
not change the association. Adjustment for use of RAS
blocking drugs or physical activity did not essentially
change the results. There was no evidence for effect
modification between BMI or WC and treatment
group with regard to kidney function decline (data not
shown). When WC, instead of BMI, was taken as deter-
minant, results were comparable. On average, BMI and
WC did not change during follow-up, with a mean (SD)
change of 0.03 (1.67) kg/m2 and 0.14 (5.99) cm. Change
in BMI was not associated with annual eGFRcysC
decline. The regression coefficient for each unit decline
in BMI was –0.052 (0.129 to 0.024). Likewise, decline
in WC was not associated with eGFRcysC decline.
Finally, taking eGFRcr-cysC as the outcome, analysis
resulted in slightly weaker effect estimates
(Supplementary Material, Tables S5 and S6).
Discussion
This is the first study to show a progressive association
between adiposity and kidney function decline in stable
post-MI patients receiving optimal pharmacological
treatment. The mean annual decline in kidney func-
tion was –1.45ml/min/1.73 m2 for men and
0.92ml/min/1.73m2 for women. Obese men and
women showed, on average, 30% and 45% faster
annual kidney function decline than individuals of
normal weight. Each 5 kg/m2 increment of BMI
was associated with an additional annual kidney func-
tion decline of –0.35ml/min/1.73m2 in men and
0.21ml/min/1.73 m2 in women. Finally, men and
women with high versus normal WC experienced a
more rapid decline in kidney function.
The annual kidney function decline of –1.3ml/min/
1.73 m2 observed in our study is lower than the
2.2ml/min/1.73 m2 for post-MI patients found in
the Prevention of Renal and Vascular End-stage
Disease study, possibly because the patients in our
Table 3. Association of body mass index (BMI) and waist circumference (WC) with annual cystatin C based kidney function decline
in 2410 post-myocardial infarction patients, overall and for men and women separately.
Additional annual eGFRcysC decline, mean (95% CI)
Total, n¼ 2410 Men, n¼ 1914 Women, n¼ 496
Per 5 kg/m2 increment of BMI
Crude –0.20 (–0.37 to –0.02) –0.27 (–0.48 to –0.06) –0.15 (–0.48 to 0.19)
Model 1 –0.28 (–0.46 to –0.11) –0.36 (–0.57 to –0.15) –0.15 (–0.49 to 0.19)
Model 2 –0.28 (–0.46 to –0.10) –0.35 (–0.56 to –0.14) –0.21 (–0.55 to 0.14)
Per 10 cm increment of WC
Crude –0.24 (–0.36 to –0.11) –0.19 (–0.35 to –0.04) –0.19 (–0.46 to 0.08)
Model 1 –0.21 (–0.34 to –0.08) –0.21 (–0.37 to –0.06) –0.19 (–0.46 to 0.08)
Model 2 –0.20 (–0.34 to –0.07) –0.21 (–0.36 to –0.06) –0.22 (–0.49 to 0.06)
CI: confidence interval; eGFRcysC: cystatin C based estimated glomerular filtration rate.
Kidney function based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, 2012.13
Model 1: adjusted for treatment group, age and sex (if not stratified for).
Model 2: model 1, additionally adjusted for current smoking, alcohol use, level of education.
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cohort received more optimal cardiovascular drug
treatment.5 Other researchers have reported a mean
annual eGFR decline of 1.0ml/min/1.73m2 in a
community-based cohort (mean age 55 years) and
1.8ml/min/1.73m2 in healthy individuals (mean age
72 years).19,20 The size of the association between high
BMI and WC on kidney function decline that we
found was small. However, a persistently slower
kidney function decline may postpone or prevent
chronic kidney disease (CKD) in patients at high
risk, which is clinically relevant. In addition, we
recently showed in the Alpha Omega Cohort Study
a linear increase in mortality risk (cardiovascular
and non-cardiovascular) for patients with an eGFR
below 80ml/min/1.73 m2.4 Preservation of kidney
function is therefore important, especially in these
high-risk patients.
Few studies have examined the association between
BMI and kidney function decline. One study found that
in younger healthy adults, being overweight or obese
was associated with 1.50 and 1.85 times higher risk of
rapid kidney function decline (>3% eGFR per year)
compared to normal weight individuals.2 Others have
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Figure 1. (a) Association between body mass index (BMI) and (b) waist circumference (WC) and annual kidney function decline for
men and women. Linear regression coefficients for annual kidney function decline according to BMI or WC were modelled by separate
restricted cubic splines. Patients with extreme values of BMI (<20 kg/m2 (n¼ 22, 0.9%) and> 40 kg/m2 (n¼ 11, 0.5%)), or WC (<70
for women, <80 for men with BMI< 20 kg/m2 (n¼ 2 and n¼ 1) and >130 cm (n¼ 18)) were excluded. The model was adjusted for
age, treatment group and current smoking.
eGFRcysC: cystatin C based estimated glomerular filtration rate.
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(26 years), compared to older age (60 years), is asso-
ciated with double the risk of progression to CKD stage
3–5 by the age of 65.21 Interestingly, weight loss in
obese patients improves kidney function. In morbidly
obese patients aged between 18–60 years old with glom-
erular hyperfiltration, kidney function normalised after
weight loss by gastric bypass surgery.22 We found no
association between change in BMI and kidney func-
tion decline. However, BMI hardly changed during the
relative short follow-up and we had no information
whether weight loss was intentional or not. In our
study, men had a faster rate of kidney function decline
compared to women at each BMI level, but we found
no effect modification. In contrast, one meta-analysis
found that obese women versus men had a higher risk
of CKD compared to normal-weight individuals.23
In addition to BMI, we evaluated the effect of WC,
since it is a more accurate measure for visceral fat.1
The correlation coefficient of 0.8 between BMI and
WC observed here was similar to that seen in a study
which assessed patients with metabolic syndrome
(mean age 68 years).24,25 In line with our results,
others reported that individuals with high versus low
WC had a 24% versus 20% risk of annual eGFR
decline of >5%, in a multi-ethnic non-diabetic popula-
tion.25 We found for men an indication of an inverse
U-shaped association between WC (or BMI) and
eGFRcysC decline. A possible explanation is that low
weight can be a proxy of underlying disease, which is
particularly relevant in elderly patients. However, the
wide 95% CIs reflect the great uncertainty for the lower
ranges of WC and BMI.
In contrast to our results, some studies have shown
that overweight or mild obesity is reno-protective com-
pared to normal weight, both in patients with
eGFR< 60 or 60ml/min/1.73 m2.9,10 In contrast to
our study, this cohort consists of US army veterans
(95% men, mean age 73 years), with a lower mean
eGFR of 48ml/min/1.73 m2, and a large prevalence
of malignancies and lung disease. Moreover, these
studies did not control for smoking, which may have
contributed to an underestimation of the effect of
obesity, while smokers in general have lower BMI.26
Various mechanisms have been proposed through
which overweight and obesity could promote acceler-
ated loss of kidney function, in addition to diabetic and
hypertensive nephropathy. Obesity is associated with a
state of low-grade systemic inflammation, and has been
shown to cause kidney damage and eventually fibrosis
via the activity of pro-inflammatory cytokines such as
transforming growth factor b.27
This study has limitations. First, the study design is
observational, and therefore no causal inferences can be
made. Second, we estimated kidney function at only
two time points, which reduces precision of the
estimates. Third, we did not measure kidney function
directly. However, direct measurement of GFR is
cumbersome, expensive, and rarely available in large
epidemiological studies, and several reports have sug-
gested that even iothalamate measurement can have
daily variations of up to 8%.28 Fourth, no information
was available on proteinuria, an important predictor of
kidney function decline. Finally, our results are applic-
able to post-MI patients and may therefore not be gen-
eralisable to other populations. However, both the
prevalence of obesity and the prevalence of cardiovas-
cular disease show an increasing trend worldwide, and
our cohort of patients therefore represents a growing
patient group.
The study has several strengths. First, to our know-
ledge this is the only large study that explored the asso-
ciation of both BMI and WC with kidney function
decline in post-MI-patients receiving optimal pharma-
cological drug treatment, and for men and women sep-
arately. Second, we measured cysC, which is currently
the most accurate marker for estimating GFR, and in
contrast to the creatinine based eGFR is most likely not
affected by glomerular hyperfiltration.11,29
In conclusion, we found in older stable post-MI
patients that high BMI and WC were associated with
progressive cysC-based kidney function decline, despite
cardiovascular drug treatment with antihypertensive,
cholesterol-lowering, antithrombotic and glucose-low-
ering drugs. Further research is needed to study whether
prevention of obesity or weight loss intervention on-top
of cardiovascular drug treatment can slow down the
accelerated kidney function decline in post-MI patients.
Author contribution
KE, JG, EG, DK and EH contributed to conception and
design of the manuscript. KE, JG, EG, DK and EH contrib-
uted to acquisition, analysis and interpretation, and drafted
the manuscript. TS, FD and JF contributed to interpretation.
All authors critically revised the manuscript, all gave final
approval and all agreed to be accountable for all aspects of
work, ensuring integrity and accuracy.
Acknowledgements
The authors thank Eveline Waterham for retrieving the serum
samples. Eric Melse is acknowledged for data management
and graphics.
Previous presentations of this work: European Renal
Association – European Dialysis and Transplant
Association Congress 2016, May 21–24th, Vienna, Austria
(poster MP316).
Declaration of conflicting interests
The author(s) declared the following potential conflicts of
interest with respect to the research, authorship and/or pub-
lication of this article: EH is a member of the Guideline
Committee of the Dutch Federation of Nephrology. JG
Esmeijer et al. 97
received research funding from Unilever R&D for epidemio-
logical studies of dietary fatty acids and is a member of the
Standing Committee on Nutrition of the Dutch Health
Council, Working Group on Minerals of the European
Food and Safety Authority, and Dutch Academy for
Nutritional Sciences, and is a Fellow of the American Heart
Association. DK received research funding from the Royal
Netherlands Academy of Arts and Sciences and is Member of
the Dutch Academy of Nutritional Sciences. KE, TS, JF, FD
and EG report that they have no disclosures.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship and/or publication of this
article: Financial support was obtained from the Dutch
Kidney Foundation (PV41; EH), the Dutch Heart
Foundation (JG and DK) and the National Institutes of
Health (JG and DK). The grant from the Dutch Kidney
Foundation covered baseline and final examinations of
kidney function. The grant from the Dutch Heart
Foundation covered baseline examinations. The grant from
the National Institutes of Health covered final examinations.
The Alpha Omega Cohort Study is registered at




1. World Health Organization. Obesity: Preventing and
managing the global epidemic. Report of a WHO consult-
ation. World Health Organ Tech Rep Ser 2000; 894:
839–868.
2. Grubbs V, Lin F, Vittinghoff E, et al. Body mass index
and early kidney function decline in young adults: A lon-
gitudinal analysis of the CARDIA (Coronary Artery Risk
Development in Young Adults) study. Am J Kidney Dis
2014; 63: 590–597.
3. Lim CC, Teo BW, Ong PG, et al. Chronic kidney disease,
cardiovascular disease and mortality: A prospective cohort
study in a multi-ethnic Asian population. Eur J Prev
Cardiol 2015; 22: 1018–1026.
4. Hoogeveen EK, Geleijnse JM, Giltay EJ, et al. Kidney
function and specific mortality in 60–80 years old post-
myocardial infarction patients: A 10-year follow-up
study. PLoS One 2017; 12: e0171868.
5. Eijkelkamp WB, de Graeff PA, van Veldhuisen DJ, et al.
Effect of first myocardial ischemic event on renal function.
Am J Cardiol 2007; 100: 7–12.
6. Holzmann MJ, Carlsson AC, Hammar N, et al. Chronic
kidney disease and 10-year risk of cardiovascular death.
Eur J Prev Cardiol 2016; 23: 1187–1194.
7. Bavbek N, Isik B, Kargili A, et al. Association of obesity
with inflammation in occult chronic kidney disease.
J Nephrol 2008; 21: 761–767.
8. Tomaszewski M, Charchar FJ, Maric C, et al. Glomerular
hyperfiltration: A new marker of metabolic risk. Kidney
Int 2007; 71: 816–821.
9. Lu JL, Kalantar-Zadeh K, Ma JZ, et al. Association of
body mass index with outcomes in patients with CKD.
J Am Soc Nephrol 2014; 25: 2088–2096.
10. Lu JL, Molnar MZ, Naseer A, et al. Association of age
and BMI with kidney function and mortality: A cohort
study. Lancet Diabetes Endocrinol 2015; 3: 704–714.
11. KDIGO. Kidney disease – improving global outcomes:
KDIGO 2012 clinical practice guideline for the evalu-
ation and management of chronic kidney disease.
Kidney Int 2013; 3: 18–23.
12. Kromhout D, Giltay EJ, Geleijnse JM, et al. n-3 Fatty
acids and cardiovascular events after myocardial infarc-
tion. N Engl J Med 2010; 363: 2015–2026.
13. Inker LA, Schmid CH, Tighiouart H, et al. Estimating
glomerular filtration rate from serum creatinine and
cystatin C. N Engl J Med 2012; 367: 20–29.
14. Hoogeveen EK, Geleijnse JM, Kromhout D, et al. Effect
of omega-3 fatty acids on kidney function after myocar-
dial infarction: The Alpha Omega Trial. Clin J Am Soc
Nephrol 2014; 9: 1676–1683.
15. Hoogeveen EK, Geleijnse JM, Kromhout D, et al. No
effect of n-3 fatty acids on high-sensitivity C-reactive pro-
tein after myocardial infarction: The Alpha Omega Trial.
Eur J Prev Cardiol 2014; 21: 1429–1436.
16. Bozeman SR, Hoaglin DC, Burton TM, et al. Predicting
waist circumference from body mass index. BMC Med
Res Methodol 2012; 12: 115.
17. Harrell FJ. Regression modelling strategies: With applica-
tions to linear models, logistic regression, and survival ana-
lysis. New York: Springer ScienceþBusiness Media,
2001.
18. Glymour MM, Weuve J, Berkman LF, et al. When is
baseline adjustment useful in analyses of change? an
example with education and cognitive change. Am J
Epidemiol 2005; 162: 267–278.
19. Shlipak MG, Katz R, Kestenbaum B, et al. Rate of
kidney function decline in older adults: A comparison
using creatinine and cystatin C. Am J Nephrol 2009; 30:
171–178.
20. Turin TC, Jun M, James MT, et al. Magnitude of rate of
change in kidney function and future risk of cardiovas-
cular events. Int J Cardiol 2016; 202: 657–665.
21. Silverwood RJ, Pierce M, Thomas C, et al.
Association between younger age when first overweight
and increased risk for CKD. J Am Soc Nephrol 2013; 24:
813–821.
22. Bolignano D and Zoccali C. Effects of weight
loss on renal function in obese CKD patients: A sys-
tematic review. Nephrol Dial Transplant 2013; 28:
iv82–iv98.
23. Wang Y, Chen X, Song Y, et al. Association between
obesity and kidney disease: A systematic review and
meta-analysis. Kidney Int 2008; 73: 19–33.
24. Gierach M, Gierach J, Ewertowska M, et al. Correlation
between body mass index and waist circumference in
patients with metabolic syndrome. ISRN Endocrinol
2014; 2014: 514589.
25. Malkina A, Katz R, Shlipak MG, et al. Association of
obesity and kidney function decline among non-diabetic
adults with eGFR> 60ml/min/1.73 m2: Results from the
98 European Journal of Preventive Cardiology 25(1)
Multi-Ethnic Study of Atherosclerosis (MESA). Open J
Endocr Metab Dis 2013; 3: 103–112.
26. Flegal KM, Graubard BI, Williamson DF, et al. Excess
deaths associated with underweight, overweight, and
obesity. JAMA 2005; 293: 1861–1867.
27. Gupta J, Mitra N, Kanetsky PA, et al. Association
between albuminuria, kidney function, and inflammatory
biomarker profile in CKD in CRIC. Clin J Am Soc
Nephrol 2012; 7: 1938–1946.
28. Kwong YT, Stevens LA, Selvin E, et al. Imprecision of
urinary iothalamate clearance as a gold-standard measure
of GFR decreases the diagnostic accuracy of kidney func-
tion estimating equations. Am J Kidney Dis 2010; 56:
39–49.
29. Rosolowsky ET, Niewczas MA, Ficociello LH, et al.
Between hyperfiltration and impairment: Demystifying
early renal functional changes in diabetic nephropathy.
Diabetes Res Clin Pract 2008; 82: S46–S53.
Esmeijer et al. 99
